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Abstract 
            Sudden cardiac death (SCD) due to various cardiomyopathies is currently prevented by 
the implantation of an automated cardioverter/defibrillator (ICD). ICD impalntation in patients 
who are not survivors of SCD, or have not suffered potentially lethal ventricular arrhythmias, are 
based on the presence of cardiomyopathy with a reduced left ventricular ejection fraction. The 
bulk of patients who are considered suitable for an ICD implantation and receive such devices, 
do not experience device therapy shocks at follow-up ("false positives"), thus creating a climate 
of uncertainty among patients and physicians about the soundness of our current eligibility 
criteria for ICDs. In addition the cost of inappropriate ICDs is staggering, and the undue 
exposure of "false positive" patients to complications, and hardships is disconcerting. T-wave 
alternans (TWA) has emerged as a possible "risk detection of SCD" technology, but its 
reproducibility   has   not   been   tested.   Peripheral   edema   (extracardiac)   or   other  cardiac 
mechanisms, unrelated to the degree of SCD risk, alter the amplitude, and other attributes, of the 
T-waves. Since TWA may be T-wave amplitude-, or other T-wave attributes-dependent (this is 
still a speculation), a need may be emerging for its correction by the T-wave amplitude (TWA 
index); such an index may enhance the reproducibility, and evaluate the true sensitivity, 
specificity and predictive accuracy of the TWA in detecting future victims of SCD.
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              Sudden cardiac death (SCD), which is due primarily to ventricular tachycardia and 
fibrillation, accounts for ~450,000 deaths annually in the USA1 The great majority of the victims 
have ischemic cardiomyopathy consequent to a large myocardial infarct and/or ischemic dilated 
cardiomyopathy, or non-ischemic cardiomyopathy, due to a variety of other pathlophysiological 
etiologies.2 Many of these patients have clinical congestive heart failure (CHF), and experience 
dyspnea, fatigue, initially with exertion and subsequently at rest, and SCD. Also such patients 
have systolic dysfunction, as assessed by a reduced left ventricular ejection fraction (EF), 
assessed by different imaging modalities. An estimated 4.9 million people in the USA have 
CHF, with ~550,000 cases reported annually.2 Although the implementation of the implantable 
cardioverter/defibrillator (ICD) has been found extremely  effective  in  aborting  SCD  and  thus 
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saving lives,3-5 these devices are implanted to thousands of patients with low EF and CHF, who 
over the course of follow-up do not receive life saving shocks due to the overall low incidence of 
SCD in these populations.6  Indications for ICD implantation are resuscitated SCD, sustained 
ventricular tachycardia, CHF, and low EF.5  Prolonged QRS complex duration has been 
considered a pathology index for follow-up and prognosis in patients with CHF and in the 
evaluation for ICD implantation.7 This index however is under scrutiny, and of late has been 
considered   less   reliable   than   the   EF,   in   fathoming   the   suitability   of   patients   for   ICD 
implantation.8  There is a compelling need for employment of additional parameters, to the 
clinical picture and EF, in the selection of patients with CHF who have not experienced lethal 
arrhythmias (the bulk of such patients), but who nevertheless may need ICD for prevention of 
SCD; also the majority of patients with this clinical profile after having an ICD implanted, do 
not receive shock therapies at follow-up, suggesting that probably the ICD implantation was not 
indicated after all, or generating ambivalence to the physicians and patients alike, as to the 
soundness of our current criteria for employing these invasive devices.                         
T-wave   alternans                                                                                      
            Recently T-wave alternans (TWA), which reflects in its simplest form a beat-to-beat 
variation in the T wave shape, timing, and amplitude, or cardiac repolarization in general,9 has 
emerged as such plausible parameter. On March 21, 2006, the Centers for Medicare and 
Medicaid Services (CMS) issued a decision memo stating that the "Microvolt T-Wave Alternans 
diagnostic testing is covered for the evaluation of patients at risk for sudden cardiac death"; this 
coverage is provided only "when the analytic spectral method is used" for the calculation of 
TWA10 (vide infra). TWA varies in its presentation from a macroscopically (≥50 μV), easily 
visually appreciated form (described almost 100 years ago) to a microscopically occurring 
disturbance, measuring a few μV in amplitude, which requires special algorithms for its 
detection. The beat-to beat variation may range from alternating change in amplitude of the T-
waves to alternating T-waves of opposite polarity. TWA is calculated with a variety of methods, 
taking into consideration various attributes of cardiac repolarization. Two methods have 
emerged and are dominant currently, one employing spectral analysis using the fast Fourier 
transformation,11 and another employing a time domain analysis, using the "modified moving 
average"   approach,12  with   the   former   implemented   in   a   commercially   available   device 
(Cambridge   Heart,   Bedford,   MA).13  The   patient   is   tested   either   invasively   in   the 
electrophysiology laboratory, where cardiac pacing is being used for its elicitation,14,15  or 
noninvasively (the currently favored approach) in the context of exercise testing (bicycle 
ergometry, or treadmill),16  with the purpose of modestly increasing the heart rate, or by 
implementing ambulatory (Holter) ECG monitoring.12 Additionally if exercise is not thought to 
be feasible in a patient, pharmacological means (e.g., dobutamine) for increasing the heart rate 
may be used in the implementation of TWA testing. A rise in heart rate is required for 
emergence of TWA, since even patients with severe CHF do not show TWA at rest, but only 
very rarely. Since TWA with rapid heart rates may not be pathological, and may even be elicited 
in normal individuals ("false positive" response), there is a critical rise in the heart rate (usually 
≤110beats/min), which is recommended for the assessment of clinically meaningful detection of 
TWA.13-17 Also the magnitude of TWA in μV is dependent on the heart rate and thus pacing-, or 
exercise-induced heart rate rise within a narrow range elicits progressively larger responses of 
TWA values in μV.18 The last attests to the dependence of the magnitude of TWA on the heart 
rate rise. TWA measurement, using the above 2 methods,11,12 elicits values of different order of 
magnitude, with the spectral method reporting much lower values, and mainly in a qualitative 
form with an abnormal cutoff point of ≥ 1.9 μV. Nevertheless reporting data in quantitative form 
has been increasingly encouraged and felt to be advantageous.18,19 The phenomenon of TWA 
may assume complex forms,9 but the clinically evaluated, and the commonest form, is that of the 
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alternating beat-to-beat variation in the T-wave. Recently the elicitation of TWA employing 
simultaneous ventricular and atrial stimulation in the context of an electrophysiologic procedure 
has been implemented in patients who have suffered an acute myocardial infarction, and has 
been found to have superior sensitivity and specificity, and a lower rate of indeterminate tests 
(vide infra), over the procedure using atrial stimulation, or the noninvasive version based on 
exercise   testing.20  Most   recently   a   comparison   of   TWA   assessment   using   atrial   versus 
ventricular pacing, showed the latter to be superior.21 Thus the way to enhance sensitivity and 
specificity and to minimize the rate of indeterminate tests appears to be an invasive-based 
procedure. Of note is that while TWA measurements/calculations/mathematical data treatment, 
when based on exercise testing or right atrial pacing, are carried out on the repolarization signals 
of intrinsic ventricular beats, when based on ventricular pacing, the repolarization signals 
consequent to an artificially paced ventricular beats are dealt with.                         
Reproducibility   of   T-wave   alternans                                                                
            The reproducibility of a diagnostic test is of paramount importance for reliance on it, for 
decision-making. Thus it is expected that back-to-back performance of a test should lead to 
reasonably similar values; also tests performed hours, days, weeks, or even years apart should 
generate reasonably close values, providing that the clinical status of the tested patient is about 
the same during the 2 testing incidences. The EF e.g., the main laboratory parameter along with 
clinical assessment currently employed in the selection of patients for ICD implantation, is 
expected to be stable when tested repeatedly with the same method, and provided that no 
worsening or improvement of the patient has been documented in the intervening time period. In 
fact when EF values are significantly different on repeat testing, an investigation is launched to 
detect the reasons for such discrepancy. The same reproducibility, relied upon in different 
modalities, should be expected from TWA. Long-term reproducibility of TWA has not been 
evaluated. As of July 7, 2007, 387 titles were listed in Pub Med in response to the inquiry 
phrased as "T-wave alternans; none of these entries actually deals even tangentially with the 
problem of reproducibility of the method. By this I mean comparing data from 2 TWA tests (of 
any type), done at 2 different time points (days, months, or years apart), in a cohort of clinically 
stable patients, ensuring that measurements were made at identical heart rates. Only a few 
studies measuring short-term reproducibility have been published,14-17 and they were based on 
back-to-back testing or tests performed a few hours apart, or involved use of a drug during the 
repeat TWA testing (not real reproducibility studies).14,15 Studies on short-term and long-term 
reproducibility are needed, if  TWA testing is to become a clinical tool for evaluation of patients 
with CHF for ICD implantation. It needs to be demonstrated that TWA is present or absent, or in 
the former situation of a certain stable value of magnitude, when a patient with CHF is at the 
same state of clinical compensation, as assessed by symptoms, signs of disease, and routine 
laboratory   testing.                                                                  
Magnitude   of   T-wave   alternans                                                              
            An important issue of concern, among others, is the current consideration that a patient is 
"positive" when a TWA ≥1.9 μV is found on testing,9 which appears counterintuitive to what is 
expected in biological systems. An absolute "cutoff point" or threshold above which pathology is 
ascribed must be suspect; accordingly the increasing magnitude of TWA with increasing heart 
rates, the association with more severe pathology when TWA is found at rest or with slow heart 
rates, and the recently reported notion that "size matters after all",19,22 suggests that TWA should 
become a quantitative assessment. However the issue of the variation of the TWA in response to 
the increasing heart rate during exercise testing is not a problem in implementing TWA testing 
to be solved, since exercise is confined to levels that increase the heart rates to ~110 beats /min.9 
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This also applies to the invasive assessment of TWA by pacing.14,15,20,21 Nevertheless pacing the 
patient incrementally, or exercising so that data on TWA are provided at heart rates of 90, 100, 
110, and 120 beats per minute may be important when comparing repeat TWA tests of a single 
individual, or a cohort of patients. TWA is also affected by several other mechanisms, including 
autonomic nervous system tone, and various drugs.23 Adrenergic stimulation elicits or enhances 
TWA,24 and beta-blockers lead to attenuation of the TWA.14,15 However it has been suggested 
that for patients with CHF taking beta-blockers, there is no need to stop these essential drugs 
prior to testing the patients for TWA.9,14 Indeed intuitively it appears appropriate to implement 
TWA testing while the patients are on their "routines", in terms of their maintenance drugs, since 
in such a setting also experience their risk of SCD. Finally a disconcerting matter is that of the 
"indeterminancy"   of  TWA  tests,  and the  notion  that  there is  scientific  justification  for 
considering such tests as "positive",25 which makes some uneasy, about such trend.26                             
"T-wave amplitude dependence" of the T-wave alternans                                                         
            Although more problems may be encountered, as the TWA testing is being implemented 
in practice and research, the balance of the present exposition focuses on the change in the T-
wave amplitude as confounding factor in the implementation of this modality. These issue needs 
to be addressed presently for optimization of the application of the TWA testing.27,28 Finally the 
reproducible placement of the limb, and especially precordial, leads in repeat TWA testing 
cannot be overemphasized; vast experience in the exercise stress laboratory has shown that 
deviations from the standard positioning of recording electrodes (unfortunately a very common 
encounter) can cause major changes in the amplitude, shape and duration of T-waves, and thus 
possibly affect the magnitude of TWA (vide infra). Such variations in the positioning of the 
precordial lead electrodes on the chestwall are particularly important, since they are the most 
useful (e.g., V2-V4), or often preferred, for TWA analysis.19                                  
Peripheral edema and T-wave amplitude                                                               
            Changes in the amplitude of T-waves may be traced to electrophysiological causes (real), 
or extracardiac mechanisms (apparent). A supportive argument for the latter is the recent 
demonstration that peripheral edema (frequently present in patients with CHF) results in 
reversible attenuations of the amplitude of the P-waves, QRS complexes and T-waves,29-34 with 
corresponding shortening of QRS complexes and QTc intervals.35,36 All these changes are not 
electrophysiologically mediated, but are the result of the increased fluid content of the 
electrically "passive" volume conductor enveloping the heart due to fluid volume overload. It 
should be envisaged that TWA happens at the action potential, extracellular, and epicardial 
levels, but electrical currents of its signature are transmitted to the recording sites at the body 
surface, and in the process undergo transfer alterations due to the intervening inhomogeneous 
collection of organs and tissues.37-39 Why should the magnitude of TWA be "immune" to such 
influences, if all other amplitudes and intervals are influenced by the changes in the extra-
cardiac milieu, and if TWA is dependent on the T-wave amplitude? (vide infra). If one considers 
for a moment that not only the presence, but also the magnitude, of TWA is of clinical 
significance the reported attenuation of the ECG voltage29-34 must have some effect on the TWA 
value. T-waves are also subjected to reduction in amplitude in edematous states34 including 
CHF, and such amplitude attenuations possibly may affect the values of TWA. It should be 
emphasized here that such fluid overload conditions are frequent in patients with CHF, even if 
they are not clearly clinically apparent; the patient with CHF may have accumulated several 
liters of interstitial fluid before peripheral edema becomes clinically apparent.40 Theoretically if 
a patient with CHF has e.g., TWA of 5.0 μV magnitude in state "A", based on measured T-wave 
amplitude of 200 μV in beat "a" in e.g., lead V3,  and  195 μV  in  beat  "b",  a  supervening 
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edematous state "B", which has imparted a 50% reduction of the ECG voltage, from the onset of 
the P-wave to the offset of the T-wave, will result in T-waves of 100 μV in beat "a", 97.5 μV in 
beat "b", and a calculated TWA of 2.5 μV. Even if one considers that the absolute value of ≥1.9 
μV in a patient suffices to characterize the testing for TWA as "positive", the emergence of the 
above described  extracardiac  mechanism could lead to a TWA value of <1.9 μV, and a 
"negative" test. In a more complex model, where both changes in the body volume conductor, 
and  cardiac  electrophysiological alterations are expected, it will be problematic to separate 
actual   (electrophysiologically   mediated),   from   apparent   (extracardiac)   influences   on   the 
magnitude of TWA. Moreover changes in the amplitude of T-waves occur occasionally in 
clinically stable patients without an apparent reason; such changes in the T-wave amplitude may 
lead to calculated TWA of different magnitude (as per argument above) when quantitation is 
used,   or   render   a   different   qualitative   characterization   ("positive",   "negative",   or 
"indeterminate"). In addition to apparent (in the setting of CHF), real (electrophysiologically 
mediated) changes in the amplitude of T-waves should not be always considered as reflecting 
variations in the SCD risk, but may be due to a large variety of influences known to change the 
T-wave amplitude; nevertheless such T-wave amplitude changes might also possibly engender 
changes in the TWA magnitude, as argued above.                                                       
A need for a T-wave alternans INDEX                                                                         
            Based on the above, what has been proposed is an index of TWA (TWAI),41 which 
corrects, adjusts, or normalizes, for the specific amplitude of the T-waves at the time point of a 
particular assessment of TWA. The correction is applied to the output of any conceivable 
algorithm measuring/calculating the TWA, and includes the spectral measurement,13 the time-
domain analysis using the "modified moving average",9,12 or any future mathematical treatment 
of the T-wave/overall repolarization data. Such output values in μV are placed in the numerator 
of a fraction, with the amplitude of the corresponding T-wave in μV placed in the denominator. 
By the "T-wave" herein it is implied the taller T-waves of the 2, in the "ababab" sequence 
encountered in the phenomenon of TWA. Also different data, instead of the T-wave amplitude, 
can be substituted in both the numerator and the denominator and depending on the algorithm 
implemented in the measurement/calculation of the "TWA".  Thus if other than amplitude 
information pertaining to parts of the T-wave, or ST-segment, or combinations are used for the 
TWA assessment (numerator), similar information derived from the taller T-wave will be 
substituted in the denominator.  This correction of TWA data can be applied to the T-waves of 
individual leads 1, aVF, and V1(V2), or leads V2-V4,  or the orthogonal Frank leads, or the 
vector magnitude lead.  In the last situation the denominator will comprise the square root of the 
sums of the squared values of the amplitudes of the T-waves from the 3 contributing leads.41 The 
TWAI, although a theoretical construct, has plausible physiological underpinnings. Whether it 
has any incremental value would be decided upon by its implementation in research and 
practice.
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